Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304950 | 0.86 | KMT2A (0.48) | KMT2AMEN1MAPTADRB2SLC7A5 | |
| SCHEMBL13019890 | 0.83 | KMT2A (0.40) | KMT2ACHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL2303698 | 0.82 | KMT2A (0.39) | KMT2AMEN1CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL3866624 | 0.78 | KMT2A (0.38) | KMT2AMEN1CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL2305233 | 0.78 | KMT2A (0.39) | KMT2AMEN1CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL4549587 | 0.77 | ALDH1A1 (0.47) | KMT2AMEN1CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL23559771 | 0.76 | CACNA1I (0.37) | SLC7A5 | |
| SCHEMBL506299 | 0.74 | CHRNB2 (0.42) | KMT2ACHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL3374593 | 0.74 | PPARA (0.54) | KMT2AMEN1MAPTMAP4K4SLC22A12 | |
| SCHEMBL6381688 | 0.74 | KMT2A (0.42) | KMT2AMEN1CHRNB2CHRNA4CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| WO-2015092610-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | KMT2A 2502/4885MEN1 4665/4885CHRNB2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.